The Role of Epigenetics in Periodontal and Systemic Diseases and Smoking: A Systematic Review
Abstract
:1. Introduction
2. Methods and Materials
2.1. Reporting Format and Study Registration Registration
2.2. PECO Question: Population, Exposure, Comparison, and Outcomes
2.3. Eligibility Criteria
2.3.1. Inclusion Criteria
- Human clinical studies, including both interventional and observational studies: randomized controlled trials, cohort studies, case-control studies, and cross-sectional studies.
- Studies describing either an association in epigenetic marks (global, site-specific or genome-wide methylation of DNA) or histone modifications (methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation).
- Studies assessing epigenetic changes from any type of human tissue (e.g., gingival tissues, blood, etc.).
- Studies comparing periodontal and systemic diseases with non-diseased OR studies comparing periodontal diseases in smokers and non-smokers with non-diseased.
2.3.2. Exclusion Criteria
- Systematic reviews, case reports, animal trials, and letters to editors.
- Studies describing epigenetic markers other than DNA methylation and histone modification, such as noncoding RNAs.
2.4. Types of Outcomes Measured
2.5. Search Strategy
2.5.1. Electronic Database Search
2.5.2. Hand Searching
2.5.3. Ongoing and Unpublished Clinical Trials
2.6. Data Collection and Analysis
2.6.1. Study Selection
2.6.2. Data Extraction and Analysis
2.6.3. Study Quality
3. Results
3.1. Literature Selection Process
3.2. Description of Included Studies
General Characteristics of Included Studies
3.3. Study Design
3.4. Setting and Study Population
3.5. Assessed Methylated Gene Sites
3.6. Methods for Detecting DNA Methylation Changes
3.7. Characteristics of the Outcomes Measured
3.7.1. Individual Study Outcomes
DNA Methylation of Candidate Genes
- (a)
- Methylation of candidate genes in periodontitis and metabolic disorder.
- (b)
- Methylation of candidate genes in periodontitis and rheumatoid arthritis.
- (c)
- Methylation of candidate genes in periodontitis and cancer.
- (d)
- Methylation of candidate genes in periodontitis and smokers/non-smokers.
Genome Wide Methylation
3.8. Pooled Data
3.8.1. DNA Methylation of Candidate Genes
3.8.2. Global and Genome-Wide Methylation
3.9. Study Quality
4. Discussion
4.1. Patients with Systemic Diseases
4.1.1. Smokers and Non-Smokers
4.1.2. Limitations and Confounding Variables
4.1.3. Future Research
4.1.4. Clinical Relevance
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Papapanou, P.N.; Sanz, M.; Buduneli, N.; Dietrich, T.; Feres, M.; Fine, D.H.; Flemmig, T.F.; Garcia, R.; Giannobile, W.V.; Graziani, F. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Periodontol. 2018, 89, S173–S182. [Google Scholar] [CrossRef] [Green Version]
- Page, R.C. The role of inflammatory mediators in the pathogenesis of periodontal disease. J. Periodontal Res. 1991, 26, 230–242. [Google Scholar] [CrossRef]
- Page, R.C.; Kornman, K.S. The pathogenesis of human periodontitis: An introduction. Periodontology 2000 1997, 14, 9–11. [Google Scholar] [CrossRef] [PubMed]
- Borrell, L.N.; Papapanou, P.N. Analytical epidemiology of periodontitis. J. Clin. Periodontol. 2005, 32 (Suppl. S6), 132–158. [Google Scholar] [CrossRef]
- Takashiba, S.; Naruishi, K. Gene polymorphisms in periodontal health and disease. Periodontology 2000 2006, 40, 94–106. [Google Scholar] [CrossRef]
- Kornman, K.S. Mapping the pathogenesis of periodontitis: A new look. J. Periodontol. 2008, 79, 1560–1568. [Google Scholar] [CrossRef]
- Adcock, I.M.; Tsaprouni, L.; Bhavsar, P.; Ito, K. Epigenetic regulation of airway inflammation. Curr. Opin. Immunol. 2007, 19, 694–700. [Google Scholar] [CrossRef]
- Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6–21. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsson, L.; Castilho, R.M.; Giannobile, W.V. Epigenetics and its role in periodontal diseases: A state-of-the-art review. J. Periodontol. 2015, 86, 556–568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Larsson, L. Current concepts of epigenetics and its role in periodontitis. Curr. Oral Health Rep. 2017, 4, 286–293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khouly, I.; Braun, R.S.; Ordway, M.; Aouizerat, B.E.; Ghassib, I.; Larsson, L.; Asa’ad, F. The Role of DNA Methylation and Histone Modification in Periodontal Disease: A Systematic Review. Int. J. Mol. Sci. 2020, 21, 6217. [Google Scholar] [CrossRef]
- Robertson, K.D.; Wolffe, A.P. DNA methylation in health and disease. Nat. Rev. Genet. 2000, 1, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Barros, S.P.; Offenbacher, S. Epigenetics: Connecting environment and genotype to phenotype and disease. J. Dent. Res. 2009, 88, 400–408. [Google Scholar] [CrossRef]
- Javaid, N.; Choi, S. Acetylation-and methylation-related epigenetic proteins in the context of their targets. Genes 2017, 8, 196. [Google Scholar] [CrossRef] [Green Version]
- Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074–1080. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bäckdahl, L.; Bushell, A.; Beck, S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int. J. Biochem. Cell Biol. 2009, 41, 176–184. [Google Scholar] [CrossRef]
- Ivanov, M.; Barragan, I.; Ingelman-Sundberg, M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol. Sci. 2014, 35, 384–396. [Google Scholar] [CrossRef] [PubMed]
- Glant, T.T.; Mikecz, K.; Rauch, T.A. Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 2014, 12, 35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carson, C.; Lawson, H.A. Epigenetics of metabolic syndrome. Physiol. Genom. 2018, 50, 947–955. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36. [Google Scholar] [CrossRef] [PubMed]
- Soory, M. Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management? Open Access Rheumatol. Res. Rev. 2010, 2, 1. [Google Scholar] [CrossRef] [Green Version]
- Renvert, S.; Berglund, J.S.; Persson, G.R.; Söderlin, M.K. The association between rheumatoid arthritis and periodontal disease in a population-based cross-sectional case-control study. BMC Rheumatol. 2020, 4, 1–8. [Google Scholar] [CrossRef]
- Nibali, L.; Tatarakis, N.; Needleman, I.; Tu, Y.-K.; D’Aiuto, F.; Rizzo, M.; Donos, N. Association between metabolic syndrome and periodontitis: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2013, 98, 913–920. [Google Scholar] [CrossRef] [Green Version]
- Arora, M.; Weuve, J.; Fall, K.; Pedersen, N.L.; Mucci, L.A. An exploration of shared genetic risk factors between periodontal disease and cancers: A prospective co-twin study. Am. J. Epidemiol. 2010, 171, 253–259. [Google Scholar] [CrossRef] [Green Version]
- Chapple, I.L.; Bouchard, P.; Cagetti, M.G.; Campus, G.; Carra, M.C.; Cocco, F.; Nibali, L.; Hujoel, P.; Laine, M.L.; Lingström, P. Interaction of lifestyle, behaviour or systemic diseases with dental caries and periodontal diseases: Consensus report of group 2 of the joint EFP/ORCA workshop on the boundaries between caries and periodontal diseases. J. Clin. Periodontol. 2017, 44, S39–S51. [Google Scholar] [CrossRef] [Green Version]
- Lod, S.; Johansson, T.; Abrahamsson, K.; Larsson, L. The influence of epigenetics in relation to oral health. Int. J. Dent. Hyg. 2014, 12, 48–54. [Google Scholar] [CrossRef] [PubMed]
- Leite, F.R.; Nascimento, G.G.; Scheutz, F.; Lopez, R. Effect of smoking on periodontitis: A systematic review and meta-regression. Am. J. Prev. Med. 2018, 54, 831–841. [Google Scholar] [CrossRef]
- Albandar, J.M.; Streckfus, C.F.; Adesanya, M.R.; Winn, D.M. Cigar, pipe, and cigarette smoking as risk factors for periodontal disease and tooth loss. J. Periodontol. 2000, 71, 1874–1881. [Google Scholar] [CrossRef] [PubMed]
- Tonetti, M.S. Cigarette smoking and periodontal diseases: Etiology and management of disease. Ann. Periodontol. 1998, 3, 88–101. [Google Scholar] [CrossRef] [PubMed]
- Haber, J.; Wattles, J.; Crowley, M.; Mandell, R.; Joshipura, K.; Kent, R.L. Evidence for cigarette smoking as a major risk factor for periodontitis. J. Periodontol. 1993, 64, 16–23. [Google Scholar] [CrossRef] [PubMed]
- Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009, 6, e1000100. [Google Scholar] [CrossRef] [PubMed]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [Green Version]
- National Heart, L.; Institute, B. Quality assessment tool for observational cohort and cross-sectional studies. Bethesda Natl. Inst. Health Dep. Health Hum. Serv. 2014. [Google Scholar]
- Grdovic, N.; Rajic, J.; Petrovic, S.M.; Dinic, S.; Uskokovic, A.; Mihailovic, M.; Jovanovic, J.A.; Tolic, A.; Pucar, A.; Milasin, J.; et al. Association of CXCL12 gene promoter methylation with periodontitis in patients with diabetes mellitus type 2. Arch. Oral Biol. 2016, 72, 124–133. [Google Scholar] [CrossRef] [PubMed]
- Kojima, A.; Kobayashi, T.; Ito, S.; Murasawa, A.; Nakazono, K.; Yoshie, H. Tumor necrosis factor-alpha gene promoter methylation in Japanese adults with chronic periodontitis and rheumatoid arthritis. J. Periodontal Res. 2016, 51, 350–358. [Google Scholar] [CrossRef] [PubMed]
- Ishida, K.; Kobayashi, T.; Ito, S.; Komatsu, Y.; Yokoyama, T.; Okada, M.; Abe, A.; Murasawa, A.; Yoshie, H. Interleukin-6 gene promoter methylation in rheumatoid arthritis and chronic periodontitis. J. Periodontol. 2012, 83, 917–925. [Google Scholar] [CrossRef]
- Planello, A.C.; Singhania, R.; Kron, K.J.; Bailey, S.D.; Roulois, D.; Lupien, M.; Line, S.R.; de Souza, A.P.; De Carvalho, D.D. Pre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation. Oncotarget 2016, 7, 15772–15786. [Google Scholar] [CrossRef]
- Wang, Y.J.; He, L.; Yuan, M.; Tsang, W.W.; Hao, L.; Wang, M.; Chow, L.W.; Cheung, M.N.; Liu, Q.; Ng, E.L.; et al. Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of status of chronic inflammation and cancer. Int. J. Biol. Markers 2014, 29, e208–e214. [Google Scholar] [CrossRef] [PubMed]
- Loo, W.T.; Jin, L.; Cheung, M.N.; Wang, M.; Chow, L.W. Epigenetic change in E-cadherin and COX-2 to predict chronic periodontitis. J. Transl. Med. 2010, 8, 110. [Google Scholar] [CrossRef] [Green Version]
- Cho, Y.D.; Kim, P.J.; Kim, H.G.; Seol, Y.J.; Lee, Y.M.; Ku, Y.; Rhyu, I.C.; Ryoo, H.M. Transcriptomics and methylomics in chronic periodontitis with tobacco use: A pilot study. Clin. Epigenet. 2017, 9, 81. [Google Scholar] [CrossRef] [Green Version]
- De Oliveira, N.F.; Andia, D.C.; Planello, A.C.; Pasetto, S.; Marques, M.R.; Nociti, F.H., Jr.; Line, S.R.; De Souza, A.P. TLR2 and TLR4 gene promoter methylation status during chronic periodontitis. J. Clin. Periodontol. 2011, 38, 975–983. [Google Scholar] [CrossRef]
- Oliveira, N.F.; Damm, G.R.; Andia, D.C.; Salmon, C.; Nociti, F.H., Jr.; Line, S.R.; de Souza, A.P. DNA methylation status of the IL8 gene promoter in oral cells of smokers and non-smokers with chronic periodontitis. J. Clin. Periodontol. 2009, 36, 719–725. [Google Scholar] [CrossRef]
- Schulz, S.; Immel, U.D.; Just, L.; Schaller, H.-G.; Glaeser, C.; Reichert, S. Epigenetic characteristics in inflammatory candidate genes in aggressive periodontitis: The role of interleukin 17C. Med. Genet. 2014, 26, 177. [Google Scholar]
- Richter, G.M.; Kruppa, J.; Munz, M.; Wiehe, R.; Hasler, R.; Franke, A.; Martins, O.; Jockel-Schneider, Y.; Bruckmann, C.; Dommisch, H.; et al. A combined epigenome- and transcriptome-wide association study of the oral masticatory mucosa assigns CYP1B1 a central role for epithelial health in smokers. Clin. Epigenet. 2019, 11, 105. [Google Scholar] [CrossRef] [PubMed]
- Winfield, J.; Esbitt, A.; Seutter, S.F.; Desai, B.; Abdo, M.; Vasconez, M.; Laidlaw, W.; Green, K.; Shamseddin, S.M.; Borghaei, R.C. Effect of inflammatory cytokines on DNA methylation and demethylation. FASEB J. 2016, 30, 1053. [Google Scholar]
- Duarte, P.M.; da Rocha, M.; Sampaio, E.; Mestnik, M.J.; Feres, M.; Figueiredo, L.C.; Bastos, M.F.; Faveri, M. Serum levels of cytokines in subjects with generalized chronic and aggressive periodontitis before and after non-surgical periodontal therapy: A pilot study. J. Periodontol. 2010, 81, 1056–1063. [Google Scholar] [CrossRef] [PubMed]
- Salvi, G.; Brown, C.; Fujihashi, K.; Kiyono, H.; Smith, F.; Beck, J.; Offenbacher, S. Inflammatory mediators of the terminal dentition in adult and early onset periodontitis. J. Periodontal Res. 1998, 33, 212–225. [Google Scholar] [CrossRef]
- Offenbacher, S.; Barros, S.P.; Beck, J.D. Rethinking periodontal inflammation. J. Periodontol. 2008, 79, 1577–1584. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, K.; Takashiba, S.; Nagai, A.; Takigawa, M.; Myoukai, F.; Kurihara, H.; Murayama, Y. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J. Periodontol. 1994, 65, 147–153. [Google Scholar] [CrossRef]
- Löe, H. Periodontal disease: The sixth complication of diabetes mellitus. Diabetes Care 1993, 16, 329–334. [Google Scholar] [CrossRef]
- Mealey, B.L.; Ocampo, G.L. Diabetes mellitus and periodontal disease. Periodontology 2000 2007, 44, 127–153. [Google Scholar] [CrossRef] [Green Version]
- Tezal, M.; Sullivan, M.A.; Hyland, A.; Marshall, J.R.; Stoler, D.; Reid, M.E.; Loree, T.R.; Rigual, N.R.; Merzianu, M.; Hauck, L. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol. Prev. Biomark. 2009, 18, 2406–2412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zeng, X.-T.; Deng, A.-P.; Li, C.; Xia, L.-Y.; Niu, Y.-M.; Leng, W.-D. Periodontal disease and risk of head and neck cancer: A meta-analysis of observational studies. PLoS ONE 2013, 8, e79017. [Google Scholar] [CrossRef] [PubMed]
- Romandini, M.; Baima, G.; Antonoglou, G.; Bueno, J.; Figuero, E.; Sanz, M. Periodontitis, Edentulism, and Risk of Mortality: A Systematic Review with Meta-analyses. J. Dent. Res. 2021, 100, 37–49. [Google Scholar] [CrossRef] [PubMed]
- Söder, B.; Yakob, M.; Meurman, J.H.; Andersson, L.C.; Klinge, B.; Söder, P.-Ö. Periodontal disease may associate with breast cancer. Breast Cancer Res. Treat. 2011, 127, 497–502. [Google Scholar] [CrossRef]
- Hujoel, P.P.; Drangsholt, M.; Spiekerman, C.; Weiss, N.S. An exploration of the periodontitis–cancer association. Ann. Epidemiol. 2003, 13, 312–316. [Google Scholar] [CrossRef]
- Zhang, S.; Barros, S.; Niculescu, M.; Moretti, A.; Preisser, J.; Offenbacher, S. Alteration of PTGS2 promoter methylation in chronic periodontitis. J. Dent. Res. 2010, 89, 133–137. [Google Scholar] [CrossRef]
- Borojevic, T. Smoking and periodontal disease. Mater. Socio-Med. 2012, 24, 274. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, K.W.; Pausova, Z. Cigarette smoking and DNA methylation. Front. Genet. 2013, 4, 132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cekici, A.; Kantarci, A.; Hasturk, H.; Van Dyke, T.E. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontology 2000 2014, 64, 57–80. [Google Scholar] [CrossRef] [Green Version]
- Gamonal, J.; Acevedo, A.; Bascones, A.; Jorge, O.; Silva, A. Characterization of cellular infiltrate, detection of chemokine receptor CCR5 and interleukin-8 and RANTES chemokines in adult periodontitis. J. Periodontal Res. 2001, 36, 194–203. [Google Scholar] [CrossRef] [PubMed]
- Yucel-Lindberg, T.; Brunius, G. Epidermal growth factor synergistically enhances interleukin-8 production in human gingival fibroblasts stimulated with interleukin-1β. Arch. Oral Biol. 2006, 51, 892–898. [Google Scholar] [CrossRef]
- Andia, D.C.; Planello, A.C.; Portinho, D.; Da Silva, R.A.; Salmon, C.R.; Sallum, E.A.; Junior, F.H.N.; de Souza, A.P. DNA methylation analysis of SOCS1, SOCS3, and LINE-1 in microdissected gingival tissue. Clin. Oral Investig. 2015, 19, 2337–2344. [Google Scholar] [CrossRef]
- De JH Martinez, C.; Villafuerte, K.R.; Luchiari, H.R.; de O. Cruz, J.; Sales, M.; Palioto, D.B.; Messora, M.R.; Souza, S.L.; Taba, M., Jr.; Ramos, E.S. Effect of smoking on the DNA methylation pattern of the SOCS1 promoter in epithelial cells from the saliva of patients with chronic periodontitis. J. Periodontol. 2019, 90, 1279–1286. [Google Scholar] [CrossRef]
- Baptista, N.; Portinho, D.; Casarin, R.; Vale, H.; Casati, M.; De Souza, A.; Andia, D. DNA methylation levels of SOCS1 and LINE-1 in oral epithelial cells from aggressive periodontitis patients. Arch. Oral Biol. 2014, 59, 670–678. [Google Scholar] [CrossRef]
Study/Year | Design/Study Period | Setting, Location, Funding, and COI | N Patients- SEX | Mean Age in Years (SD/Range) | Racial/Ethnic Background | Eligibility Criteria | Smokers |
---|---|---|---|---|---|---|---|
Periodontitis compared to those with metabolic disorders vs. healthy controls | |||||||
(Grdovic et al., 2016) [34] | Cross-sectional 2013–2015 | University, Serbia Funding: governmental COI: none | 1. CP: 29 13F/16M 2. CP/T2D: 22 6F/16M 3. Controls: 21 13F/8M | 1. CP: 48.17 ± 13.48 2. CP/DM: 56.36 ± 8.7 3. Controls: 33.43 ± 5.28 | Caucasians of Serbian nationality | Excluded: A systemic disease except for T2D, systemic antibiotic/immunomodulatory therapy within 3 months, therapy of periodontitis during 1.5 years prior to the study, and daily usage of oral antiseptics | Included: Smokers Differences in percentage of DNA methylation between smokers and non-smokers was analyzed |
Periodontitis compared to those with RA vs. healthy controls | |||||||
(Ishida et al., 2012) [36] | Observational 2007–2008 | University, Japan Funding: governmental COI: none | 1. CP: 30 20F/10M 2. RA: 30 27F/3M 3. Controls: 30 20F/10M | 1. CP: 62.3 ± 1.5 (45–76) 2. RA: 60.0 ± 2.2 (31–83) 3. Controls: 53.4 ± 2.7 (29–75) | Japanese | Excluded: The history of periodontal therapy within the previous 6 months, the presence of 15 teeth, pregnancy, and DM | Included: Current smokers, former smokers, or never smokers |
(Kojima et al., 2016) [35] | Observational 2013–2014 | University, Japan Funding: governmental COI: none | 1. CP: 30 22F/8M 2. RA: 30 25F/5M 3. Controls: 30 24F/6M | 1.CP: 64.4 ± 1.5 2. RA: 61.0 ± 2.0 3. Controls: 63.3 ± 1.8 | Japanese | Excluded: DM, periodontal therapy within the previous 3 months, and the presence of fewer than 15 teeth | Excluded: All smokers |
Periodontitis compared to those with cancer vs. healthy controls | |||||||
(Loo, Jin, Cheung, Wang, and Chow, 2010) [39] | Prospective Cohort Study 2004–2009 | University, China Funding: governmental COI: none | 1. CP: 110 22 F/88 M 2. BRCA: 106 F/M: NR 3. Controls: 108 39F/69M | 1. CP: 42.9 ± 9.71 18–65 2. BRCA: 56.2 (26–85) 3. Controls: 42.8 ± 9.69 (18–60) | NR | Included: Free from systemic or chronic disease, current and past non-smokers, no swelling of the lymph nodes, no TMJ disease, no soft tissue abnormalities or severe dental caries, and no furcation involvement or generalized gingival recession | Included: Current and past non-smokers |
(Wang et al., 2014) [38] | Observational 2011–2013 | University, China Funding: governmental COI: none | 1. CP: 110 37F/73M 2. BRCA: 108 108F/0M 3. Controls: 180 80F/100M | 1. CP: 44.2 ± 1.5 (18–65) 2. BRCA: 56.2 ± 6.8 3. Controls: 45.6 ± 2.4 (18–60) | NR | Excluded: Systemic or chronic disease, lymph node swelling, TMJ disease, soft tissue abnormalities, severe dental caries, and furcation involvement or generalized gingival recession | Included: Current and past non-smokers |
(Planello et al., 2016) [37] | Cohort study NR | University, Brazil Funding: public foundation COI: none | 1. CP: 19 54.3% F/45.6% M 2. OSCC: 301 samples (+ adjacent normal samples: 34) F/M: NR 3. Controls: 23 63.3% F/36.3% M | 1. CP: 47.17 ± 11.31 2. SCC: NR 3. Controls: 42.54 ± 11.94 | NR | Included: no systemic disorder that could affect the periodontal condition, not on antibiotics/anti-inflammatory medication (the past 6 months), non-pregnant/lactating and non-alcoholics | Included: Non-smokers |
Smoker/Non-Smoker Study Groups | |||||||
(Oliveira et al., 2009) [42] | Cohort Study (prospective observational) NR | University, Brazil Funding: public foundation COI: none | 1. CP/S: 30 13F/17M 2. CP/NS: 40 24F/16M 3. NP/NS: 41 27F/14M | 1. CP/S: 47.03 ± 6.49 2. CP/NS: 44.94 ± 9.17 3. NP/NS: 46.2 ± 14.1 | NR (Southeastern portion of Brazil) | Included: Good general health Excluded: Any systemic disorder that would affect the periodontal condition (except smoking), pregnancy or lactation, and systemic antibiotics or anti-inflammatory medication within 6 months | Included: Smokers 30/111 subjects |
(De Oliveira et al., 2011) [41] | Cohort Study (prospective observational) NR | University, Brazil Funding: public foundation COI: none | 1. CP/S: 11 5F/6M 2. CP/NS: 12 8F/4M 3. NP/NS: 11 7F/4M | 1. CP/S: 45.7 ± 7.4 2. CP/NS: 45.5 ± 10.1 3. NP/NS: 39.8 ± 15.5 | NR (Southeastern portion of Brazil) | Included: Good general health Excluded: A systemic condition that could affect periodontal condition (excluding smoking), pregnancy or lactation, systemic antibiotics or anti-inflammatory medications within 6 months | Included: Smokers 11/34 subjects |
(Cho et al., 2017) [40] | Cohort Study (prospective observational) NR | NR, NR Funding: governmental COI: none | 1. CP/S: 5 1F/4M 2. CP/NS: 5 4F/1M 3. NP/S: 5 0F/5M 4. NP/NS: 5 2F/3M | 1. CP/S: 56 (52–56) 2. CP/NS: 53 (52–55) 3. NP/S: 52 (47–54) 4. NP/NS: 44 (41–55) | NR | Included: Generally healthy patients Excluded: Acute or AgP, any severe systemic disease that could affect periodontal condition, pregnancy or lactation, systemic antibiotics or anti-inflammatory medications within 6 months | Included: Smokers 10 of 20 subjects |
Author and Year | Methodology | Results/Conclusions | Clinical Parameters | |||||||
---|---|---|---|---|---|---|---|---|---|---|
N Cases per Study Group | Criteria for Subject Allocation | Adjustment (e.g., Age, Sex, Smoking, Number of Teeth etc.) | Type of Tissue (and Site Collected, if Applicable) | Methylation Sites (Genes) Assessed | Methods for Detecting DNA Methylation Changes | Main Findings | Additional Observations/Outcomes Assessed | Global/Genome-Wide Reporting | ||
Periodontitis compared to those with metabolic disorders vs. healthy controls | ||||||||||
(Grdovic et al., 2016) [34] | 1. CP: 29 2. CP/T2D: 22 3. Controls: 21 | 1. CP: AAP classification, 1999; and no SD. 2. CP/T2D: ADA, 2013 3. Controls: No signs of periodontitis, and no SD; further clinical parameters NR. Nondiabetics: normal parameters on OGTT and HbA1c < 6.5% (ADA, 2013). | Pearson’s correlation coefficient was determined with adjustment for age including all subjects | Buccal Epithelial Cells | CXCL2 | MSP | CXCL12: Highest percent of DNA methylation in CP/T2D. CXCL12 promoter predominantly unmethylated in all groups. Increased frequency of the methylated form and increased percent of methylation of CXCL12 promoter in CP and CP/T2D group vs. controls, although without statistical significance. | A statistically significant relationship between the extent of DNA methylation of the CXCL12 promoter and periodontal parameters, as well as between DNA methylation of CXCL12 and glycosylated hemoglobin. | NR | (mean; SD) 1. CP: PI (Silness-Loe): 1.66 ± 0.79 * BOP (%):63.64 ± 27.66 * PPD: 2.77 ± 0.59 mm * CAL: 3.12 ± 1.47 mm * 2. CP/T2D: PI (Silness-Loe): 2.17 ± 0.78 *# BOP (%): 63.21 ± 30.33 * PPD: 2.73 ± 0.91 mm * CAL: 4.06 ± 2.22 mm *# 3. Controls: PI (Silness-Loe): 0.97 ± 0.58 BOP (%): 36.84 ± 20.59 PPD: 1.93 ± 0.45 mm CAL: 0.08 ± 0.28 mm * Statistically significantly different from Control # Statistically significantly different from CP |
Periodontitis compared to those with RA vs. healthy controls | ||||||||||
(Ishida et al., 2012) [36] | 1. CP: 30 2. RA: 30 3. Controls: 30 | 1. CP: AAP classification, 1999. 2. RA: ARA, 1987, and disease activity classification (Leeb, 2005). 3. Controls: No signs of periodontitis, no sites with PD > 3 mm, and no SD. | Adjustment for age, sex, and smoking status | Peripheral Blood | IL6 | Bisulfite genomic sequencing | IL6 gene CpG motifs −74 bp: Methylation levels significantly lower in RA and CP vs. controls (p = 0.0001). + 19 bp: Differential levels of methylation among groups, not associated with serum levels of IL-6. 17 CpG motifs: Comparable levels of the methylation between the groups. The hypomethylated status of CpG in the IL6 promoter region may lead to increased levels of serum IL-6, implicating a role in the pathogenesis of RA and CP. | RA (vs. CP and controls): fewer remaining teeth (p < 0.05). RA and CP (vs. control): more severe levels of PD and CAL. Both levels of serum IL6 and IL6 production by mononuclear cells were significantly different between individuals with and without the methylation at 74 bp (p = 0.03). | NR | (mean; SE) 1. CP: PD: 2.8 ± 0.1mm * CAL: 3.2 ± 0.2mm * 2. RA: PD: 3.0 ± 0.1 mm * CAL: 3.2 ± 0.2 mm * 3. Controls: PD: 2.2 ± 0.1 mm CAL: 2.2 ± 0.1 mm * Statistically significantly different from Control |
(Kojima et al., 2016) [35] | 1. CP: 30 2. RA: 30 3. Controls: 30 | 1. CP: AAP classification, 1999. 2. RA: ARA classification, 1987, and the ACR and the ELAR, 2010. 3. Controls: no signs of periodontitis, no CAL > 3 mm. | NR | Peripheral blood | TNF | Direct sequencing of genomic DNA | TNF: Hypermethylated in CP and RA. Significantly higher methylation rates and frequencies at seven and six CpG sites, respectively, and overall methylation rates in RA vs. controls. | Methylation rates and methylation frequencies in patients with RA were not influenced by medication with a steroid that suppressed TNF expression. | NR | (mean; SE) 1. CP: BOP (%): 20.0 ± 3.3 * PD: 2.9 ± 0.1mm * CAL: 3.2 ± 0.2mm * 2. RA: BOP (%): 9.9 ± 1.9 PD: 2.7 ± 0.1 mm * CAL: 3.0 ± 0.1 mm * 3. Controls: BOP (%): PD: 2.2 ± 0.1 mm CAL: 2.2 ± 0.1 mm * Statistically significantly different from Control |
Periodontitis compared to those with cancer vs. healthy controls | ||||||||||
(Loo, Jin, Cheung, Wang, and Chow, 2010) [39] | 1. CP: 110 2. BRCA: 106 3. Controls: 108 | 1. CP: periodontal disease for over 5 years and had SRP every 6 months. Further classification NR. 2. BRCA: Pathologically confirmed invasive ductal carcinoma BRCA patients. 3. Controls: Periodontitis-free; further clinical parameters NR. | NR | Peripheral blood (control), GT (CP), and BRCA neoplastic tissue | CDH1 and COX2 | MSP | CDH1 and COX2: Hypermethylation highest in BRCA followed by CP, and more frequently than in controls; hypermethylation correlated among the three groups with statistical significance (p < 0.0001). | The relative risk of CP associated with CDH1 and COX2 was 0.1091 and 0.0485. | NR | (mean; SD) 1. CP: PD: 5.5 ± 1.12 mm Calculus (%):61.5 ± 24.63 BOP (%): 76.49 ± 19.13 2. BRCA: NR 3. Control: PD: 3.0 ± 0.45 mm Calculus (%):17.14 ± 6.85 BOP (%): 13.77 ± 6.69 |
(Wang et al., 2014) [38] | 1. CP: 110 2. BRCA: 108 3. Controls: 180 | 1. Periodontitis: periodontal disease for over 5 years and had SRP every 6 months. Further classification NR. 2. BRCA: Pathologically confirmed invasive ductal carcinoma BRCA patients. 3. Controls: No signs of periodontitis, and no SD; further clinical parameters NR. | NR | Peripheral blood (from all groups), GT (from CP), and BRCA neoplastic tissue | TIMP3, GSTP1 and 14-3-3 sigma genes | MSP | TIMP3 and GSTP1: Hypermethylation of periodontitis and controls were similar, but both were significantly lower than those for BRCA (p < 0.0001). 14-3-3 sigma: Methylation in chronic inflammatory gum disease was higher than in the cancer and controls (p < 0.0001). | Epigenetic silencing of 14-3-3 sigma occurred more frequently in the chronic inflammation group than in cancer patients and healthy controls. | NR | (mean; SD) 1. CP: PD: 5.5 ± 2.2 mm * Calculus (%): 63.0 ± 11.8 BOP (%): 61.3 ± 11.4 * CAL: 5.5 ± 0.9 mm 2. BRCA: NR 3. Control: PD: 2.1 ± 0.9 mm Calculus (%): 34.1 ± 10.6) BOP (%): 29.53 ± 7.2 CAL: 0.0 mm * Statistically significantly different from Control |
(Planello et al., 2016) [37] | 1. CP: 19 2. Controls: 23 3. OSCC: 301 samples (+adjacent normal samples: 34) | 1. CP: AAP classification, 1999 and 2004. 2. Controls: No clinical sign/symptoms of periodontal disease. 3. OSCC: from the oral cavity, SCC and adjacent normal was obtained from TCGA. | NR | GT | SOCS1, RMI2 | Infinium-based DNA Methylation Analysis, PCR, MS-HRM | SOCS1, RMI2: Hypermethylated CpG sites in CP were also hypermethylated in OSCC, and hypomethylated CpG sites in CP were also hypomethylated in OSCC. | Chronically inflamed tissues have a pre-neoplastic epigenome characterized by global hypomethylation and focal hypermethylation of enhancers. The DNA methylation pattern links CP to OSCC. | Global methylation pattern in CP was significantly altered when compared to normal tissue. In total, 127 hyper-methylated putative enhancers in CP were obtained. DNA-seq profiles of over 100 human cell lines from 79 different cell types were generated through the ENCODE project. DNA hypermethylation directly disrupts the transcriptional enhancer activity, leading to the shortening of telomere in the described chronic conditions. | NR |
Smoker/Non-Smoker Study Groups | ||||||||||
(Oliveira et al., 2009) [42] | 1. CP/S: 30 2. CP/NS: 40 3. NP/NS: 41 | 1. CP/S: At least three teeth exhibiting sites ≥5 mm CAL, at least 2 different quadrants; smokers: 5 cigarettes/day for at least 5 years. 2. CP/NS: At least three teeth exhibiting sites ≤5 mm CAL, in at least 2 different quadrants; never smoked. 3. NP/NS: No signs of periodontal disease (absence of CAL, no sites with PD > 3 mm); and never smoked. | NR | GT | CXCL8 | MSP | CXCL8: higher percentage hypomethylation in CP, independent of smoking habit, (p = 0.0001); higher percentage methylation in controls than CP and CP. | Higher levels of CXCL8 mRNA vs. controls in gingival cells (p = 50.007). No significant differences among groups were observed in gingival cells and blood cells. Smoking was not found to interfere with the loss of methylation in the cells collected in the mouthwash. | NR | (Mean; SD) 1. CP/S: PD: 7.8 ± 2.02 mm 2. CP/NS: PD: 7.9 ± 2.18 mm 3. NP/NS: NR |
(De Oliveira et al., 2011) [41] | 1. CP/S: 11 2. CP/NS: 12 3. NP/NS: 11 | 1. CP/S: at least three teeth exhibiting sites ≥5 mm CAL in at least 2 different quadrants; smokers: 5 cigarettes/day for at least 5 years. 2. CP/NS: At least three teeth exhibiting sites ≤ 5 mm CAL in at least 2 different quadrants, and never smoked. 3. NP/NS: No signs of periodontal disease, (absence of CAL, and PPD ≤ 3 mm), and never smoked. | NR | GT | TLR2 and TLR4 | PCR and Methylation analysis with specific restriction enzymes | TLR2: no difference among groups (p = 40.05). TLR4: no statistical differences were found among these groups (p > 0.05). | N/A | NR | (Mean; SD) 1. CP/S: PD: 7.8 ± 1.9 mm FMBS (%): >25 2. CP/NS: PD: 7.4 ± 2.1 mm FMBS (%): >25 3. NP/NS: PD: NR FMBS (%): ≤25 |
(Cho et al., 2017) [40] | 1. CP/S: 5 2. CP/NS: 5 3. NP/S: 5 4. NP/NS: 5 | 1. CP/S: PD ≥ 6 mm, BOP, and ABL. Smoked for at least 5 years; quantity/frequency NR. 2. CP/NS: PD ≥ 6 mm, BOP, and ABL. Never smoked. 3. NP/S: No BOP, no ABL, and PPD ≤ 4 mm. Smoked for at least 5 years; quantity/frequency NR. 4. NP/NS: No BOP, no ABL, and PPD ≤ 4 mm. Never smoked. | NR | GT | ECM related organization genes | Illumina NextSeq500 sequencing system | ECM organization-related genes: Smoking is closely associated with ECM organization-related genes. Differential gene expression pattern; i.e., increased in CP/S vs. CP/NS and NP/S. | PPI analysis: performed for 17 genes exhibiting inverse correlation of DNA methylation with gene expression between (NN and NP) and (SN and SP). In total, 157 genes were identified as potentially affected by PPI. Among them, 50 genes were differentially expressed and 107 genes showed no change between the non-smoker and smoker groups. | Between NN and SN: In total, 84 genes were differently methylated; 36 were hypermethylated, and 48 were hypo-methylated in SN. Between NP and SP: In total, 96 genes; 30 were hypermethylated, and 66 were hypo-methylated in SP. DE and DM genes that did not overlap were 7 and 16, respectively. Finally, three were identified with NN and SN, while between NP and SP cases, there were seven genes. | NR |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Khouly, I.; Braun, R.S.; Ordway, M.; Ghassib, I.; Larsson, L.; Asa’ad, F. The Role of Epigenetics in Periodontal and Systemic Diseases and Smoking: A Systematic Review. Appl. Sci. 2021, 11, 5269. https://doi.org/10.3390/app11115269
Khouly I, Braun RS, Ordway M, Ghassib I, Larsson L, Asa’ad F. The Role of Epigenetics in Periodontal and Systemic Diseases and Smoking: A Systematic Review. Applied Sciences. 2021; 11(11):5269. https://doi.org/10.3390/app11115269
Chicago/Turabian StyleKhouly, Ismael, Rosalie Salus Braun, Michelle Ordway, Iya Ghassib, Lena Larsson, and Farah Asa’ad. 2021. "The Role of Epigenetics in Periodontal and Systemic Diseases and Smoking: A Systematic Review" Applied Sciences 11, no. 11: 5269. https://doi.org/10.3390/app11115269